Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,548.00
Ask: 12,550.00
Change: 6.00 (0.05%)
Spread: 2.00 (0.016%)
Open: 12,570.00
High: 12,704.00
Low: 12,472.00
Prev. Close: 12,550.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - AstraZeneca PLC

21 May 2014 12:38

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION
(a) Identity of the person whose positions/dealings are being disclosed: Wellington Management Company, LLP
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: 20 May 2014
(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer? YES
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security: Ordinary Shares (GB0009895292) and ADRs (US0463531089)
Interests Short Positions
Number % Number %
(1) Relevant securities owned and/or controlled: 64,500,768 shares 5.11 %
(2) Derivatives (other than options):
(3) Options and agreements to purchase/sell:
Total 64,500,768 shares 5.11 %
(b) Rights to subscribe for new securities (including directors’ and other executive options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
Ordinary Shares (GB00098952922) Purchase 12,079 shares 42.8993 GBP
Ordinary Shares (GB00098952922) Sale 34,332 shares 43.0850 GBP
ADRs (US0463531089) Purchase 147,280 Depository Receipts (representing 147,280 shares on a converted basis) 71.8600 USD
(b) Derivatives transactions (other than options)
Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
(ii) Exercising
Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state “none”

None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None
(c) Attachments
Is a Supplemental Form 8 attached? NO
Date of disclosure 21 May 2014
Contact name John D. Norberg
Telephone number 617-790-7265

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel?s website at www.thetakeoverpanel.org.uk.

Copyright Business Wire 2014

Date   Source Headline
18th Aug 20161:00 pmRNSDirector Declaration
16th Aug 20167:00 amRNSAstraZeneca completes agreement with LEO Pharma
10th Aug 20162:41 pmRNSASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
9th Aug 20167:00 amRNSASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
1st Aug 20162:30 pmRNSTotal Voting Rights
1st Aug 201611:00 amRNSDirector/PDMR Shareholding
28th Jul 20167:00 amRNSAZN: H1 2016 Results
27th Jul 20169:00 amRNSNotice of Results
19th Jul 20162:15 pmRNSQTERN (saxa/dapa) EU approved for type-2 diabetes
18th Jul 20167:00 amRNSTAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL
14th Jul 201612:07 pmRNSSecond Price Monitoring Extn
14th Jul 201612:02 pmRNSPrice Monitoring Extension
13th Jul 20167:00 amRNSAZ resolves Faslodex patent litigation in the US
1st Jul 20165:30 pmRNSTotal Voting Rights
28th Jun 20167:00 amRNSZavicefta approved in EU
23rd Jun 20167:00 amRNSAstraZeneca updates on Flumist vaccine in the US
14th Jun 20163:00 pmRNSDirector/PDMR Shareholding
9th Jun 20167:03 amRNSAZ agreement with Aspen for anaesthetics portfolio
3rd Jun 20167:00 amRNSAZ completes US licensing agreement with Ironwood
2nd Jun 20167:00 amRNSAZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH
1st Jun 201612:00 pmRNSBlock listing Interim Review
1st Jun 201611:30 amRNSTotal Voting Rights
27th May 201612:36 pmRNSPOSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
27th May 20167:03 amRNSPositive results from AstraZeneca Faslodex trial
27th May 20167:00 amRNSAstraZeneca receives CRL from US FDA for ZS-9
23rd May 20164:00 pmRNSDirector/PDMR Shareholding
18th May 20167:00 amRNSTOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL
17th May 20167:00 amRNSPOSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA
12th May 20167:00 amRNSSELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US
11th May 20165:30 pmRNSPublication of Final Terms
9th May 20165:35 pmRNSLaunch and pricing of EUR2.2bn bond issues
5th May 20163:00 pmRNSPublication of a Prospectus
3rd May 20161:30 pmRNSTotal Voting Rights
3rd May 20167:01 amRNSAstraZeneca completes divestment of Imdur
3rd May 20167:00 amRNSAZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY
29th Apr 20165:30 pmRNSResult of AGM
29th Apr 201612:46 pmRNSPOSITIVE CHMP OPINION FOR CAZ AVI
29th Apr 20167:00 amRNSAZN: 1st Quarter Results
28th Apr 20169:00 amRNSNotice of Results
26th Apr 20169:29 amRNSAZ enters US licensing agreement with Ironwood
26th Apr 20167:01 amRNSBEVESPI AEROSPHERE APPROVED BY US FDA FOR COPD
8th Apr 20167:00 amRNSAZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL
1st Apr 201611:30 amRNSTotal Voting Rights
29th Mar 20167:00 amRNSTAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS
24th Mar 20163:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20167:00 amRNSAZ reports results from Brilinta stroke trial
18th Mar 201610:30 amRNSNotice of AGM
8th Mar 20166:29 pmRNSFiling of Form 20-F with SEC
8th Mar 201612:00 pmRNSAnnual Financial Report
1st Mar 20162:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.